BDF
LXRX icon

Balasa Dinverno & Foltz’s Lexicon Pharmaceuticals LXRX Stock Holding History

Balasa Dinverno & Foltz’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-1,714
Closed -$11K – 209
2015
Q1 		$11K Buy
+1,714
New +$11.7K ﹤0.01% 203

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.03B AUM 57.21% 1-Year Est. Return
TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $12.9B AUM 31.03% 1-Year Est. Return

Balasa Dinverno & Foltz's LXRX Position: Q2 2015 in Review

Balasa Dinverno & Foltz sold out of Lexicon Pharmaceuticals (LXRX) in Q2 2015, closing a stake of 1,714 shares — an estimated $11K sold.

Balasa Dinverno & Foltz first reported a position in LXRX in Q1 2015 and held it in 1 quarter. The position peaked at $11K in Q1 2015. 94 funds tracked by Wall St. Rank hold LXRX as of Q2 2015.

  • Balasa Dinverno & Foltz reported no remaining Lexicon Pharmaceuticals position as of Q2 2015 after selling out during the quarter.
  • Balasa Dinverno & Foltz sold 1,714 Lexicon Pharmaceuticals shares in Q2 2015, an estimated $11K.
  • Balasa Dinverno & Foltz first reported a position in Lexicon Pharmaceuticals in Q1 2015 and held it in 1 quarter.
  • Balasa Dinverno & Foltz's Lexicon Pharmaceuticals position peaked at $11K in Q1 2015.
  • 94 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2015.

Based on Balasa Dinverno & Foltz's 13F filing for Q2 2015, filed 11 Aug 2015.